# Mersana Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mersana-therapeutics

- Industry: Biotechnology
- Headquarters: Cambridge, US
- Website: www.mersana.com
- Total disclosed funding: $92M
- Latest round: Series C (Jun 15, 2016)
- Investors on record: 12

## About

Mersana Therapeutics, Inc. is a US-based biotechnology company specializing in the development of innovative antibody-drug conjugates (ADCs) designed to improve cancer treatment outcomes.Founded in 2001 and headquartered in Cambridge, US, Mersana Therapeutics focuses on creating ADCs for various cancer types. The company has completed 13 deals, with a significant funding round in May 2020, raising USD 152 mn through a Private Placement by selling 8 million shares. Martin Huber serves as CEO, bringing extensive experience from his previous ventures.Mersana Therapeutics specializes in developing ADCs, utilizing proprietary platforms such as Dolasynthen and Immunosynthen to produce customized therapies targeting specific cancers. Their ADCs are currently in different phases of clinical development, catering to healthcare providers and research institutions in North America and Europe. In November 2025, Day One Biopharmaceuticals, Inc., a portfolio company of Atlas Venture, T Rowe Price, Canaan Partners, BVF Partners, Franklin Templeton, Viking Global Investors, and Access Industries agreed to fully acquire Mersana Therapeutics, Inc. from 180 Degree Capital, PureTech Ventures, F-Prime Capital, ProQuest Investments, RHO, New Enterprise Associates, Pfizer Venture Investments, and Rock Springs Capital for an upfront payment of USD 129 million and will receive additional payment of USD 156 million upon achieving milestones.

## Funding rounds

- Series C, Jun 15, 2016, $33M — New Enterprise Associates, Wellington Management, ArrowMark Partners, Rock Springs Capital, Cormorant Asset Management, Takeda Pharmaceutical
- Series D, Feb 20, 2015, $10M — New Enterprise Associates, F-Prime Capital, Pfizer Venture Investments, Rock Springs Capital
- Series C, Apr 8, 2014, $9.5M — New Enterprise Associates
- Series C, Sep 27, 2013, $5M — New Enterprise Associates
- Series C, Jul 27, 2012, $13M — New Enterprise Associates, RHO, F-Prime Capital, 180 Degree Capital, ProQuest Investments, Pfizer Venture Investments
- Series B, Aug 8, 2008, $10M — RHO, PureTech Ventures, F-Prime Capital, 180 Degree Capital, ProQuest Investments
- Series B, Nov 1, 2005, $11M — RHO, PureTech Ventures, F-Prime Capital, 180 Degree Capital, ProQuest Investments
- Series A, Feb 19, 2002, $0.8M — PureTech Ventures, 180 Degree Capital

## Investors

- PureTech Ventures — Series A, Series B
- 180 Degree Capital (https://capitalatlas.ai/funds/180-degree-capital) — Series A, Series B, Series C
- RHO (https://capitalatlas.ai/funds/rho) — Series B, Series C
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series B, Series C, Series D
- ProQuest Investments (https://capitalatlas.ai/funds/proquest-investments) — Series B, Series C
- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series C, Series D
- Pfizer Venture Investments (https://capitalatlas.ai/funds/pfizer-venture-investments) — Series C, Series D
- Rock Springs Capital — Series D, Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- ArrowMark Partners — Series C
- Cormorant Asset Management (https://capitalatlas.ai/funds/cormorant-asset-management) — Series C
- Takeda Pharmaceutical — Series C